Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

NDA FilingDaraxonrasibPositive

AI Analysis

Summary

Revolution Medicines announced that the FDA has accepted its New Drug Application for Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. The acceptance marks advancement toward potential regulatory approval for the targeted oncology therapeutic.

Outcome Details

New Drug Application accepted for review

Importance:7/10

Sentiment:

0.70

oncologypancreatic cancerNDAFDARAS-addicted cancers

Related Companies

$RVMD

Read the original article

Published by Drugs.com New Drug Applications on July 22, 2026 2:07 AM

Read Original